Airsculpt Technologies (AIRS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 5. Analyst Whit Mayo from Leerink Partners reiterated a Hold rating on the stock and has a $2.50 price target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Whit Mayo has given his Hold rating due to a combination of factors impacting Airsculpt Technologies. Despite the company reporting better-than-expected EBITDA results in the first quarter of 2025, there are ongoing challenges related to organizational growth, macroeconomic pressures, and demand. The company’s guidance for 2025 indicates a decline in revenues and EBITDA compared to the previous year, with margins also expected to remain below historical levels.
Furthermore, Airsculpt Technologies is experiencing pressure on its volume, with same-store revenues and cases declining significantly year-over-year. Although there are some early signs of improvement, such as sequential case growth and increased lead volume, these are not yet sufficient to offset the broader challenges. The company’s liquidity situation is also tight, with limited cash reserves and debt commitments that may necessitate additional financing. These factors contribute to Mayo’s decision to maintain a Hold rating on the stock.
AIRS’s price has also changed dramatically for the past six months – from $6.790 to $2.430, which is a -64.21% drop .